Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

If Eli Lilly ... drug was only approved to treat type 2 diabetes. It took a while to become popular as an off-label weight loss aid. Once it did, demand skyrocketed above what the company could ...

On Friday, Novo Nordisk released promising trial results for its obesity treatment, amycretin, which showed a significant weight loss in participants, outpacing Eli Lilly's own drug in early ...

Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by far Lilly's fastest-growing businesses, and the company's momentum in ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Eli Lilly and Company discovers, develops ... Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...